Nanordica Medical, an Estonian healthtech company, has raised €1.6 million in Series A funding to accelerate the commercialisation of its novel chronic wound dressing treatment. The round was led by 2C Ventures, with participation from Specialist VC, Superangel, Amalfi, Health Founders syndicate, and EstBAN syndicate.
The company’s flagship product, Premotiv, represents an alternative approach to conventional wound care in an era when antimicrobial resistance has become increasingly urgent. The funding will be directed toward completing a large randomised clinical study, strengthening the economic case for Premotiv, and obtaining CE marking for commercial launch across Europe.
Addressing a Critical Healthcare Gap
Nanordica Medical was founded to tackle a paradox in modern wound care: many existing products designed to accelerate healing rely on antibiotics, which contributes to the growing problem of antimicrobial resistance. Martin Koppel, associated with the company, highlighted the scale of the challenge: “Antimicrobial resistance is one of the defining healthcare challenges of this decade and most wound care products are making it worse. Nanordica has built a clinically proven alternative that doesn’t rely on antibiotics, doesn’t compromise healing, and leaves a significantly smaller environmental footprint.”
Chronic wounds represent a substantial clinical burden across Europe, affecting millions of patients and placing considerable strain on healthcare systems. Traditional treatment approaches often extend healing timelines while introducing the risk of resistant infections. Premotiv’s antibiotic-free mechanism offers clinicians and patients a potentially safer option without sacrificing efficacy.
Path to Market
The investment marks a critical milestone for the Estonian startup, enabling it to progress toward regulatory approval and broader adoption. The randomised clinical study will provide robust evidence of Premotiv’s efficacy compared to existing treatments, data essential for both clinical acceptance and reimbursement discussions with European health systems.
CE marking represents the gateway to commercial deployment across the European Union, signalling that the product meets health, safety, and environmental protection standards. Once obtained, this certification will allow Nanordica Medical to pursue partnerships with hospitals and wound care specialists across the continent.
Growing European Momentum in Healthtech
Nanordica Medical’s funding success reflects the broader maturation of the European healthtech ecosystem, where investors increasingly back founders addressing urgent clinical problems with evidence-based solutions. Estonia in particular has developed a thriving startup culture, supported by favourable regulatory conditions and entrepreneurial talent.
The focus on antimicrobial resistance solutions aligns with European health priorities, as the continent confronts the economic and clinical consequences of resistant infections. Companies tackling this challenge through innovation rather than conventional pharmaceutical development are attracting attention from both specialist investors and generalist venture capital firms seeking meaningful impact alongside financial returns.
As Nanordica Medical advances Premotiv toward commercialisation, the startup will join a growing cohort of European healthtech companies reshaping how chronic conditions are treated.